The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease
Background The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both pro...
Saved in:
| Published in: | Stem cell research & therapy Vol. 10; no. 1; pp. 182 - 13 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
21.06.2019
BioMed Central Ltd BMC |
| Subjects: | |
| ISSN: | 1757-6512, 1757-6512 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges, and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD because of their potential immunomodulatory activity. Multiple studies have been performed to explore the possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and prevention.
Methods
We systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they reported on the outcomes of interest.
Results
Ultimately, 10 studies were selected from among 413 candidates. According to our meta-analyses, compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection. Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to prolong engraftment time, as well as increase the rates of relapse and death.
Conclusions
MSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a need for further high-quality clinical trials including large numbers of patients to validate our findings. |
|---|---|
| AbstractList | The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges, and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD because of their potential immunomodulatory activity. Multiple studies have been performed to explore the possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and prevention. We systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they reported on the outcomes of interest. Ultimately, 10 studies were selected from among 413 candidates. According to our meta-analyses, compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection. Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to prolong engraftment time, as well as increase the rates of relapse and death. MSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a need for further high-quality clinical trials including large numbers of patients to validate our findings. Background The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges, and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD because of their potential immunomodulatory activity. Multiple studies have been performed to explore the possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and prevention. Methods We systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they reported on the outcomes of interest. Results Ultimately, 10 studies were selected from among 413 candidates. According to our meta-analyses, compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection. Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to prolong engraftment time, as well as increase the rates of relapse and death. Conclusions MSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a need for further high-quality clinical trials including large numbers of patients to validate our findings. Keywords: Mesenchymal stem cells, Stem cell transplantation, Graft-versus-host disease, Meta-analysis Abstract Background The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges, and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD because of their potential immunomodulatory activity. Multiple studies have been performed to explore the possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and prevention. Methods We systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they reported on the outcomes of interest. Results Ultimately, 10 studies were selected from among 413 candidates. According to our meta-analyses, compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection. Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to prolong engraftment time, as well as increase the rates of relapse and death. Conclusions MSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a need for further high-quality clinical trials including large numbers of patients to validate our findings. Background The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges, and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD because of their potential immunomodulatory activity. Multiple studies have been performed to explore the possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and prevention. Methods We systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they reported on the outcomes of interest. Results Ultimately, 10 studies were selected from among 413 candidates. According to our meta-analyses, compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection. Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to prolong engraftment time, as well as increase the rates of relapse and death. Conclusions MSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a need for further high-quality clinical trials including large numbers of patients to validate our findings. The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges, and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD because of their potential immunomodulatory activity. Multiple studies have been performed to explore the possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and prevention. We systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they reported on the outcomes of interest. Ultimately, 10 studies were selected from among 413 candidates. According to our meta-analyses, compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection. Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to prolong engraftment time, as well as increase the rates of relapse and death. MSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a need for further high-quality clinical trials including large numbers of patients to validate our findings. The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges, and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD because of their potential immunomodulatory activity. Multiple studies have been performed to explore the possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and prevention.BACKGROUNDThe use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively), in which immune cells from the donor attack healthy recipient tissues. GVHD presents both prophylactic and therapeutic challenges, and overall survival is poor. Mesenchymal stem cells (MSCs) show considerable promise in the treatment of GVHD because of their potential immunomodulatory activity. Multiple studies have been performed to explore the possible benefit of MSCs in GVHD, but the results of these studies are sometimes conflicting. Therefore, we performed a systematic review and meta-analysis to estimate the effect of MSC infusion on GVHD treatment and prevention.We systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they reported on the outcomes of interest.METHODSWe systematically searched the MEDLINE (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM databases to identify studies published before February 2018 involving patients with hematologic malignancies undergoing HSCT and receiving MSC-based or conventional therapy. We included studies if they reported on the outcomes of interest.Ultimately, 10 studies were selected from among 413 candidates. According to our meta-analyses, compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection. Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to prolong engraftment time, as well as increase the rates of relapse and death.RESULTSUltimately, 10 studies were selected from among 413 candidates. According to our meta-analyses, compared with conventional treatment, MSC therapy demonstrated substantial improvements in terms of complete response (CR) and overall survival for cGVHD. However, MSC therapy did not show substantial improvements in terms of engraftment, the incidence of aGVHD, relapse, death, death due to relapse, or death due to infection. Subgroup analyses showed that MSCs derived from the umbilical cord (U-MSCs) and MSC infusion after HSCT substantially improved engraftment and cGVHD incidence, whereas MSCs derived from bone marrow (B-MSCs) and MSC infusion before HSCT shows no improvement. In addition, B-MSCs and MSC infusion before HSCT tend to prolong engraftment time, as well as increase the rates of relapse and death.MSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a need for further high-quality clinical trials including large numbers of patients to validate our findings.CONCLUSIONSMSC infusion can reduce cGVHD but not aGVHD incidence and showed a positive effect in patients who already had aGVHD. For GVHD prevention, the use of U-MSCs and MSC infusion after HSCT were optimal for reducing cGVHD incidence and promoting engraftment, and might help decrease the incidence rate of relapse and death. However, B-MSCs and MSC infusion before HSCT may be harmful to patients and thus require serious consideration. A lack of robust evidence, owing to the small number of studies and small sample sizes, indicates a need for further high-quality clinical trials including large numbers of patients to validate our findings. |
| ArticleNumber | 182 |
| Audience | Academic |
| Author | Zhao, Lu Chen, Shanquan Li, Lanjuan Cao, Hongcui Yang, Panxin |
| Author_xml | – sequence: 1 givenname: Lu surname: Zhao fullname: Zhao, Lu organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases – sequence: 2 givenname: Shanquan surname: Chen fullname: Chen, Shanquan organization: The School of Clinical Medicine, University of Cambridge – sequence: 3 givenname: Panxin surname: Yang fullname: Yang, Panxin organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases – sequence: 4 givenname: Hongcui orcidid: 0000-0002-6604-6867 surname: Cao fullname: Cao, Hongcui email: hccao@zju.edu.cn organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases – sequence: 5 givenname: Lanjuan surname: Li fullname: Li, Lanjuan organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31227011$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl2L1DAUhousuOu6P8AbKQiiF12T9CONF8Ky-DGwIOjch9P0dJqhTcYkHdx7f7ipXdcZkW0vesh53jfNyfs0OTHWYJI8p-SS0rp662nOap4RKjI6F-JRckZ5ybOqpOzkoD5NLrzfkvjkOSFV8SQ5zSljnFB6lvxc95g6O2Bqu3REj0b1tyMMqQ84pgqHwafapD2OEOzOagxa_e2lwYHxuwFMgKCteZfuHO7RzHUKpo19hDDGhdl-46AL2R6dn3zWWx_SVnsEj8-Sxx0MHi_uvufJ-uOH9fXn7ObLp9X11U2mOKlC1paccUbyqlNQ00LlDQHF86ZuOTYMKBfAKIquKLuGko51TUEEoIJGoWir_DxZLbatha3cOT2Cu5UWtPy9YN1GgovnG1DmJWEdw1zVWBY1Ys1pkVPRsgKEEKqIXu8Xr93UjNiqeEQHw5HpccfoXm7sXlZlXQs6G7y-M3D2-4Q-yFH7eaZg0E5eMlaUVbzYakZfLugG4q9p09noqGZcXpWCcFoWOYnU5X-o-LY4ahWz0-m4fiR4cySITMAfYQOT93L17esx--qA7RGG0Hs7TPNF-2PwxeFc7gfyJ3ERoAugnPXeYXePUCLnYMsl2DIGW87BliJq-D8apZfAxSPq4UElW5Q-7mI26OTWTs7EkD0g-gX2MQx5 |
| CitedBy_id | crossref_primary_10_1186_s13287_021_02181_4 crossref_primary_10_3389_fcell_2020_587866 crossref_primary_10_1016_j_ebiom_2019_08_073 crossref_primary_10_1080_14728222_2021_1992383 crossref_primary_10_3390_biology12060792 crossref_primary_10_1007_s13346_021_00934_5 crossref_primary_10_1016_j_prp_2024_155354 crossref_primary_10_1186_s40164_023_00426_x crossref_primary_10_1093_stcltm_szac009 crossref_primary_10_1155_2023_9672658 crossref_primary_10_1016_j_omtm_2025_101527 crossref_primary_10_1183_16000617_0042_2021 crossref_primary_10_1016_j_tice_2022_101998 crossref_primary_10_3390_ijms22158121 crossref_primary_10_1007_s12015_021_10164_4 crossref_primary_10_3389_fimmu_2021_659621 crossref_primary_10_1097_SHK_0000000000001644 crossref_primary_10_3390_ijms241411530 crossref_primary_10_1186_s13287_021_02170_7 crossref_primary_10_1089_cell_2021_0043 crossref_primary_10_1186_s12935_021_02300_4 crossref_primary_10_3389_fcell_2021_663316 crossref_primary_10_3390_ijms221910474 crossref_primary_10_1080_14728222_2024_2405091 crossref_primary_10_1007_s12015_020_10086_7 crossref_primary_10_1186_s13287_021_02159_2 crossref_primary_10_3389_fphar_2022_1027961 crossref_primary_10_1016_j_transci_2024_104051 crossref_primary_10_3389_fimmu_2021_728190 crossref_primary_10_3390_biomedicines10061391 crossref_primary_10_3390_genes12122008 crossref_primary_10_1016_j_ejphar_2024_176996 crossref_primary_10_1186_s13287_025_04303_8 crossref_primary_10_3390_ijms26020847 crossref_primary_10_1089_scd_2021_0352 crossref_primary_10_1155_2022_1052166 crossref_primary_10_1080_08830185_2023_2252007 crossref_primary_10_1186_s13287_022_03112_7 crossref_primary_10_1016_j_aanat_2023_152131 crossref_primary_10_1186_s11658_023_00485_2 crossref_primary_10_2217_pme_2021_0111 crossref_primary_10_3390_nu15163558 crossref_primary_10_1042_BSR20211986 crossref_primary_10_1007_s13337_021_00743_x crossref_primary_10_3390_ijms24098126 crossref_primary_10_3389_fneur_2021_621392 crossref_primary_10_1038_s41598_020_60524_2 crossref_primary_10_1111_nep_70054 crossref_primary_10_3389_fimmu_2022_1045168 crossref_primary_10_1080_08923973_2024_2384913 crossref_primary_10_3389_fcell_2021_570179 crossref_primary_10_1186_s13287_022_02838_8 crossref_primary_10_56875_2589_0646_1111 crossref_primary_10_1002_sctm_20_0345 crossref_primary_10_3390_ijms22179231 crossref_primary_10_3389_fimmu_2020_583564 crossref_primary_10_3389_fcell_2021_749822 crossref_primary_10_3390_vaccines8010062 crossref_primary_10_1080_17474086_2020_1738214 crossref_primary_10_1016_j_intimp_2024_112689 crossref_primary_10_1186_s13287_021_02304_x crossref_primary_10_1186_s13287_025_04321_6 crossref_primary_10_3390_ijms24032987 crossref_primary_10_1016_j_bbcan_2024_189189 crossref_primary_10_1073_pnas_2404210121 crossref_primary_10_3390_ijms26125837 crossref_primary_10_1016_j_jcyt_2021_07_009 crossref_primary_10_3389_fimmu_2023_1241068 crossref_primary_10_3389_fimmu_2021_626755 crossref_primary_10_1182_blood_2019000951 crossref_primary_10_1016_j_arcmed_2023_102853 crossref_primary_10_3389_fimmu_2020_00792 crossref_primary_10_1111_apm_70012 crossref_primary_10_7717_peerj_15388 crossref_primary_10_3389_fcell_2022_951764 crossref_primary_10_1016_j_trim_2024_102130 crossref_primary_10_3389_fcell_2022_873603 crossref_primary_10_3390_ijms22179531 crossref_primary_10_1016_j_intimp_2021_107669 crossref_primary_10_1186_s13287_024_03824_y crossref_primary_10_1089_scd_2020_0191 crossref_primary_10_1186_s13287_024_03949_0 crossref_primary_10_1016_j_jtct_2022_10_030 crossref_primary_10_3389_fbioe_2020_575057 crossref_primary_10_4252_wjSC_v13_i2_177 crossref_primary_10_1016_j_intimp_2025_115018 crossref_primary_10_1186_s12951_025_03297_y crossref_primary_10_1007_s00784_023_05366_8 crossref_primary_10_3389_fimmu_2021_609544 crossref_primary_10_1177_20406207221134409 crossref_primary_10_3390_cancers16162892 crossref_primary_10_3390_ijms21030708 crossref_primary_10_1186_s12967_025_06623_y crossref_primary_10_1016_j_jds_2024_11_029 crossref_primary_10_1007_s10238_021_00701_3 crossref_primary_10_3389_fcell_2024_1380785 crossref_primary_10_3389_fphar_2022_1013740 crossref_primary_10_4274_tjh_galenos_2022_2022_0084 crossref_primary_10_1002_JLB_6MA0921_752RR crossref_primary_10_2147_ITT_S457366 crossref_primary_10_1016_j_bulcan_2022_11_001 crossref_primary_10_1186_s13063_023_07305_0 crossref_primary_10_3390_cells10040961 crossref_primary_10_3389_fcell_2020_599276 crossref_primary_10_1016_j_jcyt_2020_08_012 |
| Cites_doi | 10.1016/j.bbmt.2014.09.030 10.1016/j.exphem.2005.01.012 10.1080/1744666X.2016.1208086 10.1182/blood.V76.8.1464.1464 10.1016/j.jcyt.2012.10.002 10.1134/S0006297914120104 10.3727/096368912X655217 10.1182/blood-2005-07-2657 10.1016/j.bbmt.2009.12.426 10.1073/pnas.0603824103 10.1038/sj.leu.2405090 10.1182/blood-2005-07-2775 10.1089/scd.2010.0447 10.1111/j.1365-2141.2005.05409.x 10.1016/j.bbmt.2009.12.057 10.1038/leu.2015.89 10.1016/S2352-3026(15)00224-0 10.1002/eji.200636416 10.1016/S0301-472X(01)00769-X 10.1038/nrclinonc.2015.234 10.1097/00062752-200011000-00007 10.1155/2012/968213 10.1007/s12185-012-1218-3 10.1016/S0140-6736(09)60237-3 10.1097/TP.0b013e31825940a4 10.2174/1389450116666150722140633 10.1186/1756-8722-5-19 10.1182/blood.V116.21.1256.1256 10.1038/emm.2013.2 10.1634/stemcells.2008-0456 10.1016/S0140-6736(04)16104-7 10.1136/bmj.315.7109.629 10.1016/j.blre.2005.11.002 10.1200/JCO.2015.65.3642 10.1056/NEJMoa1203517 10.3727/096368912X663533 10.1007/s11892-016-0734-6 10.1186/1756-8722-7-14 10.1097/01.tp.0000244572.24780.54 10.1634/stemcells.2007-0381 10.1200/JCO.2010.33.7212 10.1016/j.bbmt.2012.04.005 10.1146/annurev.immunol.25.022106.141606 10.1182/blood-2004-11-4557 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION NPM ISR 7X8 5PM DOA |
| DOI | 10.1186/s13287-019-1287-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1757-6512 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_3502f2e3c8e548ee8714319d24a999c4 PMC6588914 A590715430 31227011 10_1186_s13287_019_1287_9 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: National Key Research and Development Program of China grantid: 2016YFA0101001 – fundername: National Natural Science Foundation of China grantid: 81620108028 funderid: http://dx.doi.org/10.13039/501100001809 – fundername: ; grantid: 81620108028 – fundername: ; grantid: 2016YFA0101001 |
| GroupedDBID | --- 0R~ 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACIHN ACJQM ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR IHW INH INR ISR ITC KQ8 LK8 M1P M7P M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SBL SOJ SV3 TUS UKHRP AAYXX AFFHD CITATION -56 -5G -BR 3V. ACRMQ ADINQ ALIPV C24 NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c706t-d57272036fca814c3b0ac73b8d7eb2a179a21e9f45fb10f2fb409aecabce9d63 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 116 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000472532600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1757-6512 |
| IngestDate | Tue Oct 14 19:08:24 EDT 2025 Tue Nov 04 01:57:23 EST 2025 Wed Oct 01 11:55:42 EDT 2025 Tue Nov 11 10:07:24 EST 2025 Tue Nov 04 18:02:20 EST 2025 Thu Nov 13 15:32:10 EST 2025 Thu May 22 20:58:48 EDT 2025 Thu Jan 02 22:59:10 EST 2025 Sat Nov 29 01:46:14 EST 2025 Tue Nov 18 21:13:26 EST 2025 Sat Sep 06 07:28:30 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Graft-versus-host disease Stem cell transplantation Mesenchymal stem cells Meta-analysis |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c706t-d57272036fca814c3b0ac73b8d7eb2a179a21e9f45fb10f2fb409aecabce9d63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-6604-6867 |
| OpenAccessLink | https://link.springer.com/10.1186/s13287-019-1287-9 |
| PMID | 31227011 |
| PQID | 2245612864 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3502f2e3c8e548ee8714319d24a999c4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6588914 proquest_miscellaneous_2245612864 gale_infotracmisc_A590715430 gale_infotracacademiconefile_A590715430 gale_incontextgauss_ISR_A590715430 gale_healthsolutions_A590715430 pubmed_primary_31227011 crossref_primary_10_1186_s13287_019_1287_9 crossref_citationtrail_10_1186_s13287_019_1287_9 springer_journals_10_1186_s13287_019_1287_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-06-21 |
| PublicationDateYYYYMMDD | 2019-06-21 |
| PublicationDate_xml | – month: 06 year: 2019 text: 2019-06-21 day: 21 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Stem cell research & therapy |
| PublicationTitleAbbrev | Stem Cell Res Ther |
| PublicationTitleAlternate | Stem Cell Res Ther |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | M Secco (1287_CR47) 2008; 26 A Fierabracci (1287_CR12) 2016; 17 PJ Martin (1287_CR5) 2012; 18 A Uccelli (1287_CR11) 2006; 36 S Hashmi (1287_CR2) 2016; 3 L Gao (1287_CR9) 2016; 34 F Locatelli (1287_CR49) 2017; 13 JY Cahn (1287_CR10) 2005; 106 IN Shipounova (1287_CR34) 2014; 79 A Bartholomew (1287_CR14) 2002; 30 A Corcione (1287_CR16) 2006; 107 K Liu (1287_CR25) 2011; 20 K Le Blanc (1287_CR22) 2004; 363 EJ Kim (1287_CR43) 2013; 45 PJ Martin (1287_CR8) 1990; 76 1287_CR30 1287_CR39 S Wang (1287_CR21) 2012; 5 JR Wingard (1287_CR52) 2011; 29 1287_CR35 J Xiang (1287_CR33) 2017; 21 SM Devine (1287_CR20) 2000; 7 PJ Martin (1287_CR32) 2010; 16 F Dazzi (1287_CR19) 2006; 20 H Ning (1287_CR24) 2008; 22 C Anasetti (1287_CR44) 2012; 367 1287_CR29 1287_CR28 M Remberger (1287_CR38) 2012; 96 N Petinaty (1287_CR4) 2010; 116 1287_CR27 1287_CR26 K Zhao (1287_CR37) 2015; 21 MT Van Lint (1287_CR7) 1998; 92 ZY Zhang (1287_CR45) 2009; 27 R Ramasamy (1287_CR17) 2007; 83 Z Sun (1287_CR41) 2014; 7 YY Dan (1287_CR13) 2006; 103 G Kogler (1287_CR42) 2005; 33 LL Lu (1287_CR46) 2006; 91 GM Spaggiari (1287_CR18) 2006; 107 LA Welniak (1287_CR3) 2007; 25 CK Chan (1287_CR48) 2012; 94 K Wu (1287_CR40) 2013; 22 BL Te (1287_CR51) 2015; 29 CG Kanakry (1287_CR1) 2016; 13 JL Ferrara (1287_CR6) 2009; 373 B Puissant (1287_CR15) 2005; 129 M Egger (1287_CR31) 1997; 315 KH Wu (1287_CR36) 2013; 22 J Galipeau (1287_CR23) 2013; 15 TP Griffin (1287_CR50) 2016; 16 |
| References_xml | – volume: 21 start-page: 97 issue: 1 year: 2015 ident: 1287_CR37 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2014.09.030 – volume: 33 start-page: 573 issue: 5 year: 2005 ident: 1287_CR42 publication-title: Exp Hematol doi: 10.1016/j.exphem.2005.01.012 – volume: 13 start-page: 43 issue: 1 year: 2017 ident: 1287_CR49 publication-title: Expert Rev Clin Immunol doi: 10.1080/1744666X.2016.1208086 – volume: 76 start-page: 1464 issue: 8 year: 1990 ident: 1287_CR8 publication-title: Blood. doi: 10.1182/blood.V76.8.1464.1464 – volume: 15 start-page: 2 year: 2013 ident: 1287_CR23 publication-title: Cytotherapy. doi: 10.1016/j.jcyt.2012.10.002 – volume: 79 start-page: 1363 issue: 12 year: 2014 ident: 1287_CR34 publication-title: Biochemistry (Mosc) doi: 10.1134/S0006297914120104 – volume: 22 start-page: 723 issue: 4 year: 2013 ident: 1287_CR40 publication-title: Cell Transplant doi: 10.3727/096368912X655217 – volume: 107 start-page: 367 issue: 1 year: 2006 ident: 1287_CR16 publication-title: Blood. doi: 10.1182/blood-2005-07-2657 – ident: 1287_CR39 doi: 10.1016/j.bbmt.2009.12.426 – ident: 1287_CR28 – volume: 103 start-page: 9912 issue: 26 year: 2006 ident: 1287_CR13 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0603824103 – volume: 22 start-page: 593 issue: 3 year: 2008 ident: 1287_CR24 publication-title: Leukemia. doi: 10.1038/sj.leu.2405090 – ident: 1287_CR30 – volume: 107 start-page: 1484 issue: 4 year: 2006 ident: 1287_CR18 publication-title: Blood. doi: 10.1182/blood-2005-07-2775 – volume: 20 start-page: 1679 issue: 10 year: 2011 ident: 1287_CR25 publication-title: Stem Cells Dev doi: 10.1089/scd.2010.0447 – volume: 129 start-page: 118 issue: 1 year: 2005 ident: 1287_CR15 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2005.05409.x – volume: 16 start-page: S169 issue: 2, Supplement 2 year: 2010 ident: 1287_CR32 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2009.12.057 – volume: 29 start-page: 1839 issue: 9 year: 2015 ident: 1287_CR51 publication-title: Leukemia. doi: 10.1038/leu.2015.89 – volume: 3 start-page: e45 issue: 1 year: 2016 ident: 1287_CR2 publication-title: Lancet Haematol doi: 10.1016/S2352-3026(15)00224-0 – volume: 36 start-page: 2566 issue: 10 year: 2006 ident: 1287_CR11 publication-title: Eur J Immunol doi: 10.1002/eji.200636416 – volume: 30 start-page: 42 issue: 1 year: 2002 ident: 1287_CR14 publication-title: Exp Hematol doi: 10.1016/S0301-472X(01)00769-X – volume: 13 start-page: 132 issue: 2 year: 2016 ident: 1287_CR1 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2015.234 – volume: 21 start-page: 4679 issue: 29 year: 2017 ident: 1287_CR33 publication-title: Chin J Tissue Eng Res – volume: 7 start-page: 358 issue: 6 year: 2000 ident: 1287_CR20 publication-title: Curr Opin Hematol doi: 10.1097/00062752-200011000-00007 – ident: 1287_CR35 doi: 10.1155/2012/968213 – volume: 96 start-page: 822 issue: 6 year: 2012 ident: 1287_CR38 publication-title: Int J Hematol doi: 10.1007/s12185-012-1218-3 – ident: 1287_CR27 – volume: 373 start-page: 1550 issue: 9674 year: 2009 ident: 1287_CR6 publication-title: Lancet. doi: 10.1016/S0140-6736(09)60237-3 – volume: 94 start-page: 132 issue: 2 year: 2012 ident: 1287_CR48 publication-title: Transplantation. doi: 10.1097/TP.0b013e31825940a4 – volume: 17 start-page: 229 issue: 2 year: 2016 ident: 1287_CR12 publication-title: Curr Drug Targets doi: 10.2174/1389450116666150722140633 – volume: 5 start-page: 19 year: 2012 ident: 1287_CR21 publication-title: J Hematol Oncol doi: 10.1186/1756-8722-5-19 – volume: 116 start-page: 538 issue: 21 year: 2010 ident: 1287_CR4 publication-title: Blood doi: 10.1182/blood.V116.21.1256.1256 – volume: 45 start-page: e2 year: 2013 ident: 1287_CR43 publication-title: Exp Mol Med doi: 10.1038/emm.2013.2 – volume: 27 start-page: 126 issue: 1 year: 2009 ident: 1287_CR45 publication-title: Stem Cells doi: 10.1634/stemcells.2008-0456 – volume: 363 start-page: 1439 year: 2004 ident: 1287_CR22 publication-title: Lancet. doi: 10.1016/S0140-6736(04)16104-7 – volume: 92 start-page: 2288 issue: 7 year: 1998 ident: 1287_CR7 publication-title: Blood. – ident: 1287_CR26 – volume: 315 start-page: 629 issue: 7109 year: 1997 ident: 1287_CR31 publication-title: BMJ. doi: 10.1136/bmj.315.7109.629 – volume: 20 start-page: 161 issue: 3 year: 2006 ident: 1287_CR19 publication-title: Blood Rev doi: 10.1016/j.blre.2005.11.002 – volume: 34 start-page: 2843 issue: 24 year: 2016 ident: 1287_CR9 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.65.3642 – volume: 367 start-page: 1487 issue: 16 year: 2012 ident: 1287_CR44 publication-title: N Engl J Med doi: 10.1056/NEJMoa1203517 – volume: 22 start-page: 2041 issue: 11 year: 2013 ident: 1287_CR36 publication-title: Cell Transplant doi: 10.3727/096368912X663533 – volume: 16 start-page: 42 issue: 5 year: 2016 ident: 1287_CR50 publication-title: Curr Diab Rep doi: 10.1007/s11892-016-0734-6 – volume: 7 start-page: 14 year: 2014 ident: 1287_CR41 publication-title: J Hematol Oncol doi: 10.1186/1756-8722-7-14 – volume: 83 start-page: 71 issue: 1 year: 2007 ident: 1287_CR17 publication-title: Transplantation. doi: 10.1097/01.tp.0000244572.24780.54 – volume: 26 start-page: 146 issue: 1 year: 2008 ident: 1287_CR47 publication-title: Stem Cells doi: 10.1634/stemcells.2007-0381 – volume: 29 start-page: 2230 issue: 16 year: 2011 ident: 1287_CR52 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.7212 – volume: 91 start-page: 1017 issue: 8 year: 2006 ident: 1287_CR46 publication-title: Haematologica. – volume: 18 start-page: 1150 issue: 8 year: 2012 ident: 1287_CR5 publication-title: Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2012.04.005 – ident: 1287_CR29 – volume: 25 start-page: 139 year: 2007 ident: 1287_CR3 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.25.022106.141606 – volume: 106 start-page: 1495 issue: 4 year: 2005 ident: 1287_CR10 publication-title: Blood. doi: 10.1182/blood-2004-11-4557 |
| SSID | ssj0000330064 |
| Score | 2.5358183 |
| SecondaryResourceType | review_article |
| Snippet | Background
The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic... The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic graft-versus-host... Background The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic... Abstract Background The use and effectiveness of hematopoietic stem cell transplantation (HSCT) are limited by lethal complications, i.e., acute and chronic... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 182 |
| SubjectTerms | Biomedical and Life Sciences Biomedical Engineering and Bioengineering Bone marrow transplantation Care and treatment Cell Biology Graft vs. host disease Graft-versus-host disease Hematopoietic stem cell transplantation Life Sciences Medical research Mesenchymal stem cells Meta-analysis Prevention Regenerative Medicine/Tissue Engineering Review Stem cell transplantation Stem Cells |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QBBIXxDeFAQEhIYGqtUnbNNwGYoLLhGCH3aI0TbYnbenTax_S7vvDZ6d55XUIuHCrGrdqbCexa_tnQt5obYQGUyKVzDTgoLSw5gpRpbYohWbc4XBoNiEOD-vjY_ltq9UX5oSN8MAj4_Z4mTHHLDe1BePa2hobdueyZYUG28YEJNBMyC1nKuzB4KbDYRvDmHld7fXgdtWYZYno_3AhZwdRwOv_fVfeOpaup0xei5uG4-jgLrkT7Ui6P37_PXLD-vvk1thZ8uIBuQTxU8wcpJ2j51hhZE4vzuEBxG2m-Le-pwtPA2Jrt-wWWMr4a4wOAfL8TI91Sf4DXUakp85T7Vs6pafj609W2g0ppnes-xSLRmiM-jwkRwefjz59SWPDhdSIrBrSthzDspUzus4Lw5sMZMWbuhXggGtYu5rlVrqidE2eOeYa8A61NboxVrYVf0R2fOftE0LBkIKTsQVfqpSFqXjj8tI4Y5kV1vDCJCTbMF-ZCEaOPTHOVHBK6kqN8lIgL4XyUjIh76ZHliMSx9-IP6JEJ0IE0Q43QLVUVC31L9VKyEvUBzVWpE5bgdovJRhmZcGzhLwOFAik4TFT50Sv-159_fF9RvQ2ErkO5mh0LHwATiH21oxyd0YJK93Mhl9tFFPhEKbHedute8UwfA0zr-CbH4-KOk2d54wJ2MUTImYqPOPNfMQvTgPQOFintczhne83yq7iDtf_mfVP_wfrn5HbDJdqVqUs3yU7w2ptn5Ob5uew6Fcvwlq_AoAiV1A priority: 102 providerName: Directory of Open Access Journals |
| Title | The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease |
| URI | https://link.springer.com/article/10.1186/s13287-019-1287-9 https://www.ncbi.nlm.nih.gov/pubmed/31227011 https://www.proquest.com/docview/2245612864 https://pubmed.ncbi.nlm.nih.gov/PMC6588914 https://doaj.org/article/3502f2e3c8e548ee8714319d24a999c4 |
| Volume | 10 |
| WOSCitedRecordID | wos000472532600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: RBZ dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: M7P dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK customDbUrl: eissn: 1757-6512 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000330064 issn: 1757-6512 databaseCode: RSV dateStart: 20100301 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfYBtJe-IYVRjEICQkUkTgfdnjb0Cb2QFV1EypPluPYXaUtqZoWae_84dw5biDjQ4KXqoovUXw5n-98d78j5JVSmiswJYKc6QIclBLWXMKzwCQpVyy2OOyaTfDRSEyn-djXcTebbPdNSNJparesRfauAb9JYJokwvfDn3yL7MBuJ7Bfw-T0c3ewEoKHDvusj2D-9s7eHuSg-n9VyD_tSNezJa-FTN1OdHznv-Zwl9z2hic9aCXlHrlhqvvkVtuK8uoB-QbyQjHVkNaWXmJJkj6_uoQbEOiZ4vF-Q-cVdRCv9aKeY-3jjzG6chjpF6otZKre04WHhqorqqqSdvns-PjZUtlVgPkg6ybAKhPqw0QPydnx0dmHj4Hv0BBoHmaroEzbOG5mtRJRouMihI8bF6Lk4LErWOyKRSa3SWqLKLTMFuBOKqNVoU1eZvEjsl3VldkjFCwv2EpLcL7SPNFZXNgo1VYbZrjRcaIHJNx8Mqk9ejk20biQzosRmWx5K4G3Enkr8wF5092yaKE7_kZ8iHLQESLqtrtQL2fSL2IZpyGzzMRaGHD0jBHYPD7KS5YosLN1MiDPUYpkW8La6Q55kOZgyaVJHA7IS0eByBsVpvbM1Lpp5MnppEf02hPZGuaola-UAE4hWFePcr9HCapB94ZfbMRZ4hDm01WmXjeSYbwbZp7BOz9uxbubehwxxkHtDwjvCX6PN_2Ran7ukMnBnBV5BM98uxF_6VVi82fWP_kn6qdkl-H6CbOARftke7Vcm2fkpv66mjfLIdniU-5-xZDsHB6NxpOhO2YZYlLvGK6NTz6NvwydyvgOK6Zi9Q |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELaggOCF-wgUahASUlFEYufkrSCqVpQValeob5bj2NuVWme1ySL1nR_OjOMNpBwSvEXxOIon4zkyM58JeSmlyiW4EmHJVAUBSg17LsmzUCdpLhk3OOwOm8gnk-L4uPzs-7jbdbX7OiXpNLXb1kX2poW4qcAySYTvh4vyMrmSgMFCwPzDoy_Dj5UIInSwsz6D-duZIxvkoPp_Vcg_WaSL1ZIXUqbOEu3e-q813CY3veNJd3pJuUMuaXuXXOuPojy_R76BvFAsNaSNoWfYkqROzs9gAgI9U_y939K5pQ7itVk0c-x9_DFGO4eRfir7Rib7li48NFRjqbQ1HerZ8fGzpTRdiPUgqzbELhPq00T3yXT3w_T9XuhPaAhVHmVdWKd9HjczShZxongVwcflVVHnELFL2OySxbo0SWqqODLMVBBOSq1kpXRZZ_wB2bCN1Y8IBc8LTGkNwVdaJirjlYlTZZRmOteKJyog0fqTCeXRy_EQjVPhopgiEz1vBfBWIG9FGZDtYcqih-74G_E7lIOBEFG33Y1mORN-EwueRswwzVWhIdDTusDD4-OyZokEP1slAdlCKRJ9C-ugO8ROWoInlyY8CsgLR4HIGxZLe2Zy1bZi_-hwRPTKE5kG1qik75QATiFY14hyc0QJqkGNhp-vxVngENbTWd2sWsEw3w0rz-CdH_biPSydx4zloPYDko8Ef8Sb8YidnzhkcnBnizKGZ75ei7_wKrH9M-sf_xP1Frm-N_10IA72Jx-fkBsM91KUhSzeJBvdcqWfkqvqazdvl8-cWvgOnMNe1A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELagHOoLNzRQqEFISKCoiXOat3KsqECrilaob5bj2NuVWme1ySL1nR_OjOMNpBwS4m0VT6L1ZA5PZuYbQp5LqQoJR4mQM1VBgFKDzqVFHuo0KyRLDC67YRPFdFoeH_MDP-e0XVe7r1OSfU8DojTZbndRm17Fy3y3hRiqxJJJhPKHH_wyuZJiHT2G64dfho8sEUTr4HN9NvO3d478kYPt_9U4_-SdLlZOXkifOq80ufnf-7lFbvgDKd3rJeg2uaTtHXKtH1F5fpd8AzmiWIJIG0PPsFVJnZyfwQ0IAE3xs39L55Y66Ndm0cyxJ_LHGu0cdvqp7Buc7Gu68JBRjaXS1nSoc8fHz5bSdCHWiazaELtPqE8f3SNHk_dHbz-EfnJDqIoo78I66_O7uVGyjFOVVBG89KQq6wIieQlGQLJYc5Nmpoojw0wFYabUSlZK8zpP7pMN21i9RSicyMDF1hCUZTxVeVKZOFNGaaYLrZJUBSRavz6hPKo5Dtc4FS66KXPR81YAbwXyVvCAvBxuWfSQHn8jfoMyMRAiGre70Cxnwiu3SLKIGaYTVWoIALUucah8zGuWSjh_qzQgOyhRom9tHWyK2Ms4nPCyNIkC8sxRICKHxZKfmVy1rdg__DwieuGJTAN7VNJ3UACnEMRrRLk9ogSToUbLT9eiLXAJ6-ysblatYJgHh53n8J8f9KI-bD2JGSvAHQSkGCnBiDfjFTs_cYjlcMwteQzPfLVWBeFNZftn1j_8J-odcv3g3UR82p9-fEQ2GapSlIcs3iYb3XKlH5Or6ms3b5dPnIX4DsP3Z7g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+role+of+mesenchymal+stem+cells+in+hematopoietic+stem+cell+transplantation%3A+prevention+and+treatment+of+graft-versus-host+disease&rft.jtitle=Stem+cell+research+%26+therapy&rft.au=Zhao%2C+Lu&rft.au=Chen%2C+Shanquan&rft.au=Yang%2C+Panxin&rft.au=Cao%2C+Hongcui&rft.date=2019-06-21&rft.pub=BioMed+Central+Ltd&rft.issn=1757-6512&rft.eissn=1757-6512&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1186%2Fs13287-019-1287-9&rft.externalDBID=ISR&rft.externalDocID=A590715430 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-6512&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-6512&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-6512&client=summon |